Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate, Shares Surge 11.8%
Dyne Therapeutics narrows Q4 loss to $0.73/share vs $0.76 estimate, shares jump 11.8% on improving trajectory and $893M cash position.
ADVERTISEMENT
Company News
BioNTech (BNTX) Reports Q4 Loss of EUR0.33/Share as COVID Vaccine Revenue Plunges; Founders Exit
BioNTech posts wider-than-expected Q4 loss of $0.33/share as COVID vaccine revenue plunges 24% year-over-year; founders to exit for new mRNA…
HPE Maintains $0.14 Quarterly Dividend With 2.61% Yield; Ex-Dividend Date March 24, 2026
HPE maintains its $0.14 quarterly dividend with a 2.7% yield; ex-date March 24, 2026.
SolarEdge (SEDG) Q4 Loss Narrows to $0.14/Share vs $0.24 Estimate, Stock Jumps 10%
SolarEdge narrows Q4 loss to $0.14/share vs $0.24 estimate, stock jumps 10% despite cautious Q1 guidance of $290M-$320M revenue.
CRISPR Therapeutics (CRSP) Reports Wider Q4 Loss of $1.37/Share on Zero Revenue; Shares Plunge 10%
CRISPR Therapeutics posts wider-than-expected Q4 loss of $1.37/share on zero revenue; shares sink 10% as cash burn accelerates.
Broadwind Energy (BWEN) Posts Q4 Loss of $0.05/Share, Revenue Climbs 10% to $37M
Broadwind Energy reports Q4 loss of $0.05 per share on revenue of $37M, up 10% year-over-year, with fiscal 2026 guidance…
Acacia Research (ACTG) Q4 Adjusted EPS Surges 122.5% YoY to $0.03, Revenue Reaches $50.1M
Acacia Research reports Q4 adjusted EPS of $0.03, up 122.5% year-over-year, with revenue of $50.1M rising 2.6% from the prior…
Acacia Research (ACTG) Returns to Profitability With $0.03 EPS in Q4 2025 on Flat $50.1M Revenue
Acacia Research swings to $0.03 adjusted EPS in Q4 2025, matching prior quarter and reversing year-ago loss, as revenue holds…
BridgeBio (BBIO) Reports Wider Q4 Loss of $1/Share vs $0.63 Estimate; Stock Surges 13%
BridgeBio posts wider-than-expected Q4 loss of $0.94/share on $154.2M revenue; stock surges 13% despite 50.6% earnings miss.
DNTH Stock Jumps 21.5% Despite Wider-Than-Expected Q4 Loss as Pipeline Prospects Fuel Rally
Dianthus Therapeutics posts wider-than-expected Q4 loss of $1.43/share on collapsing revenue, yet shares surge 21.5% on pipeline optimism.